 Day One Biopharmaceuticals NASDAQ: DAWN shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib DAY101 in relapsed or progressive pediatric low-grade glioma pLGG, the most common brain tumor diagnosed in children. . 